Tag: Synthetic DHEA derivative / NGF mimetic

  • BNN-27

    Synthetic DHEA derivative / NGF mimetic

    A synthetic DHEA derivative (17-spiroepoxy DHEA) developed at Bionature E.A. Ltd as a selective TrkA agonist mimicking NGF activity.

    Abstract

    BNN-27 (17-spiro-(2′-amino-1′,3′-thiazolin-2-yl)-androst-5-en-3-beta-ol) is a synthetic DHEA derivative developed by Bionature E.A. Ltd (Greece) and Achilleas Gravanis’s group for selective activation of TrkA, the high-affinity NGF receptor. The compound is a microneurotrophin: it mimics the NGF/TrkA pathway without binding to the p75 neurotrophin receptor (NTR). Animal studies show neuroprotective effects in models of diabetic neuropathy, retinal degeneration, and Alzheimer disease. The compound has not advanced to large clinical trials. Pharmacokinetics: oral bioavailability is good (steroid scaffold). Sold as research peptide/compound.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.